A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 8
- 试验地点
- 6
- 主要终点
- Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious events (TESAEs)
研究概览
简要总结
This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver the human frataxin (hFXN) gene to cardiac cells over a 52-week period. Long-term safety and efficacy will be evaluated for an additional 4-years for a total of 5-years post LX2006 treatment.
详细描述
Friedreich's ataxia (FA) is a rare, autosomal recessive disease caused by a mutation in the autosomal frataxin (FXN) gene. Progressive cardiomyopathy with cardiac hypertrophy and fibrosis is observed in most individuals with FA. The disease is more severe in those with earlier onset. Presently, there is no therapy that alters the progression of cardiomyopathy in FA, which is responsible for 59% of FA-related deaths.
The primary objective of this dose escalation study is to assess the safety and tolerability of three ascending doses of LX2006 in patients with FA-associated cardiomyopathy. LX2006 is designed to restore hFXN levels in order to improve mitochondrial function. Assessments of cardiac function, biomarkers and other preliminary efficacy endpoints are also included in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed genetic diagnosis of FA, with onset being before 25 years of age
- •Protocol specified ranges for antibodies
- •Protocol specified measures of FA cardiomyopathy
排除标准
- •Protocol specified ranges for left ventricular ejection fraction (LVEF) as measured by cardiac ECHO
- •Uncontrolled diabetes
- •Abnormal liver function
- •Active infection of any type, including hepatitis virus (A, B or C) or human immunodeficiency virus (HIV-1 and HIV-2)
- •Contraindication to cardiac MRI
- •Contraindications to cardiac biopsies
- •Participants who are receiving systemic corticosteroids or other immunosuppressive medications
- •History of significant coronary artery disease or any structural heart or vascular disease other than FA cardiomyopathy
- •Presence of clinically significant, hemodynamically unstable arrhythmias, requiring physician intervention
- •Presence of clinically significant abnormalities as determined by the investigator, other than ECG abnormalities related to FA
- •Uncontrolled psychiatric disease
- •Other Inclusion/Exclusion criteria to be applied as per protocol.
结局指标
主要结局
Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious events (TESAEs)
时间窗: Change from baseline to end of year 5 post dose
次要结局
- Change from baseline in LVMi(Change from baseline to end of year 5 post dose)
- Change from baseline in cardiac fibrosis as measured by cardiac MRI(Change from baseline to end of year 5 post dose)
- Change from baseline in LVEF(Change from baseline to end of year 5 post dose)
- Change from baseline in measures of cardiopulmonary exercise tolerance(Change from baseline to end of year 5 post dose)
- Presence and severity of cardiac arrythmias(Change from baseline to end of year 5 post dose)